Children in foster care are prescribed psychotropic medications

Loading the library…

For the Court

Researchers, federal auditors, and pediatric bodies agree that children in foster care receive psychotropic medication — antipsychotics and multi-drug regimens especially — at rates far above comparable Medicaid children, that the highest-risk/lowest-evidence practices concentrate in this population, and that oversight programs (prior authorization, utilization review, consultation lines) measurably reduce the prescribing. The genuine debate is aetiological and remedial: how much of the differential is warranted by the population's trauma and psychiatric burden, and how to curb inappropriate regimens without producing undertreatment.

What This Claim Does NOT Say

That any psychotropic prescription for a foster child is inappropriate — many foster children have genuine psychiatric needs, and undertreatment is also a documented risk.

That the differential is fully explained by higher need — trauma burden explains part of it, but the concentration of low-evidence practices (concomitant antipsychotics, high-level polypharmacy) and the responsiveness to oversight indicate systemic prescribing drivers beyond need.

That prescribers act in bad faith — structural drivers (placement instability, fragmented records, absent longitudinal caregivers, behavioral crises in congregate settings) shape prescribing.

That medication oversight alone fixes the problem — reviews flag prescribing without adequate psychosocial services as the persistent quality gap.

That these findings quantify harm to any individual child — they establish population-level prescribing patterns relevant to oversight and consent procedures.

Scope — Where It Holds

Applies to U.S. children in foster care, measured through Medicaid claims comparisons against non-foster Medicaid populations (TANF-enrolled and disability-qualifying comparison groups), from the 2000s growth era through the post-oversight period. The differential persists after the oversight era bent the overall trend; magnitude varies by state, age, and comparison group.

Sources & Verification

Seminal

dosReis S, Yoon Y, Rubin DM, Riddle MA, Noll E, Rothbard A (2011). Antipsychotic Treatment Among Youth in Foster Care. Pediatrics.
Cross-sectional · Medicaid-enrolled children (foster vs comparison groups)
Youth in foster care received antipsychotic medication — including concomitant (two or more simultaneous) antipsychotics — at rates far exceeding TANF-enrolled comparison youth and rivaling or exceeding youth qualifying for Medicaid by disability. Concomitant antipsychotic treatment, a practice with little pediatric evidence base, was concentrated among foster youth. The study that placed foster-care antipsychotic prescribing on the national policy agenda.
Bearing on this claim: Pediatrics claims comparison: foster youth antipsychotic and concomitant-antipsychotic use far exceeds TANF peers, rivals disability-qualifying youth.
doi.org/10.1542/peds.2010-2970

Supporting

Limits & Counter-considerations

Claims data capture prescriptions filled, not clinical appropriateness — neither over- nor under-treatment can be adjudicated per case from claims alone; foster youth carry genuinely elevated psychiatric need (see trauma-prevalence cards), so no design can fully separate need from systemic drivers; comparison groups differ across studies; and the strongest studies are state-specific, with magnitudes varying by state and era. Long-term outcome data on medicated versus unmedicated foster youth remain thin.